Becker's Healthcare December 3, 2024
Nine out of 10 drug prices negotiated by CMS remain more expensive in the U.S. compared to six other high-income countries, according to a study published Dec. 2.
After CMS released the negotiated list prices, set to take effect in 2026, researchers from universities in London, Rhode Island, San Diego and Seattle compared the new prices with those in Australia, Canada, France, Germany, Switzerland and the United Kingdom.
The analysis relied on 2021 price data — the most recent year with complete information — and converted all currencies to U.S. dollars.
Novo Nordisk’s insulin products, Fiasp...
Today's Sponsors
Today's Sponsor